Beacon Therapeutics

Beacon shines a light on positive early data from eye disease ph. 2

The company's gene therapy made for improvements in visual function for patients with X-linked retinitis pigmentosa at six months in its phase 2 study.

Zoey Becker May 7, 2025 7:15am

Moderna, Terremoto, MEI Pharma and more—Chutes & Ladders

Jul 26, 2024 8:30am

Beacon attracts $170M series B to fund eye disease gene therapy

Jul 3, 2024 5:00am